nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.457	1	CiPCiCtD
Nilotinib—BRAF—thyroid cancer	0.135	1	CbGaD
Nilotinib—TEK—Vandetanib—thyroid cancer	0.0197	0.067	CbGbCtD
Nilotinib—EPHA8—Vandetanib—thyroid cancer	0.0197	0.067	CbGbCtD
Nilotinib—MAPK11—Sorafenib—thyroid cancer	0.0179	0.0608	CbGbCtD
Nilotinib—TIE1—Sorafenib—thyroid cancer	0.0179	0.0608	CbGbCtD
Nilotinib—FGR—Vandetanib—thyroid cancer	0.017	0.0579	CbGbCtD
Nilotinib—EPHB6—Vandetanib—thyroid cancer	0.015	0.0512	CbGbCtD
Nilotinib—EPHA6—Vandetanib—thyroid cancer	0.015	0.0512	CbGbCtD
Nilotinib—LYN—Vandetanib—thyroid cancer	0.015	0.0512	CbGbCtD
Nilotinib—BLK—Vandetanib—thyroid cancer	0.015	0.0512	CbGbCtD
Nilotinib—ABL2—Vandetanib—thyroid cancer	0.0135	0.046	CbGbCtD
Nilotinib—LCK—Vandetanib—thyroid cancer	0.0123	0.0419	CbGbCtD
Nilotinib—MAP2K5—Vandetanib—thyroid cancer	0.0123	0.0419	CbGbCtD
Nilotinib—PDGFRB—Vandetanib—thyroid cancer	0.0123	0.0419	CbGbCtD
Nilotinib—BRAF—Sorafenib—thyroid cancer	0.0119	0.0404	CbGbCtD
Nilotinib—ABL1—Vandetanib—thyroid cancer	0.00977	0.0333	CbGbCtD
Nilotinib—EPHB6—Sorafenib—thyroid cancer	0.00906	0.0309	CbGbCtD
Nilotinib—EPHA6—Sorafenib—thyroid cancer	0.00906	0.0309	CbGbCtD
Nilotinib—CSF1R—Sorafenib—thyroid cancer	0.00814	0.0277	CbGbCtD
Nilotinib—PDGFRA—Sorafenib—thyroid cancer	0.00814	0.0277	CbGbCtD
Nilotinib—KIT—Sorafenib—thyroid cancer	0.00814	0.0277	CbGbCtD
Nilotinib—PDGFRB—Sorafenib—thyroid cancer	0.00741	0.0252	CbGbCtD
Nilotinib—MAP2K5—Sorafenib—thyroid cancer	0.00741	0.0252	CbGbCtD
Nilotinib—UGT1A1—Sorafenib—thyroid cancer	0.00245	0.00832	CbGbCtD
Nilotinib—ABCG2—Vandetanib—thyroid cancer	0.00223	0.0076	CbGbCtD
Nilotinib—ABCG2—Sorafenib—thyroid cancer	0.00134	0.00458	CbGbCtD
Nilotinib—Ponatinib—RET—thyroid cancer	0.00134	1	CrCbGaD
Nilotinib—CYP2B6—Sorafenib—thyroid cancer	0.000946	0.00322	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—thyroid cancer	0.000816	0.00278	CbGbCtD
Nilotinib—CYP2C8—Sorafenib—thyroid cancer	0.000716	0.00244	CbGbCtD
Nilotinib—MAPK8—neck—thyroid cancer	0.000633	0.0273	CbGeAlD
Nilotinib—CYP2B6—Doxorubicin—thyroid cancer	0.000574	0.00195	CbGbCtD
Nilotinib—CYP2C9—Sorafenib—thyroid cancer	0.0005	0.0017	CbGbCtD
Nilotinib—ABCB1—Sorafenib—thyroid cancer	0.000485	0.00165	CbGbCtD
Nilotinib—CYP3A4—Vandetanib—thyroid cancer	0.000482	0.00164	CbGbCtD
Nilotinib—CYP2D6—Sorafenib—thyroid cancer	0.000457	0.00156	CbGbCtD
Nilotinib—CDC42BPB—trachea—thyroid cancer	0.000421	0.0182	CbGeAlD
Nilotinib—EPHB3—saliva-secreting gland—thyroid cancer	0.000407	0.0176	CbGeAlD
Nilotinib—MAPK14—neck—thyroid cancer	0.000402	0.0173	CbGeAlD
Nilotinib—CA6—saliva-secreting gland—thyroid cancer	0.000355	0.0153	CbGeAlD
Nilotinib—MAPK11—thyroid gland—thyroid cancer	0.000336	0.0145	CbGeAlD
Nilotinib—EPHB2—head—thyroid cancer	0.000334	0.0144	CbGeAlD
Nilotinib—CDC42BPB—thyroid gland—thyroid cancer	0.000333	0.0144	CbGeAlD
Nilotinib—EPHA8—head—thyroid cancer	0.000321	0.0138	CbGeAlD
Nilotinib—EPHA3—thyroid gland—thyroid cancer	0.000316	0.0136	CbGeAlD
Nilotinib—EPHB3—trachea—thyroid cancer	0.000314	0.0135	CbGeAlD
Nilotinib—MAPK8—thyroid gland—thyroid cancer	0.000301	0.013	CbGeAlD
Nilotinib—MAPK11—head—thyroid cancer	0.000298	0.0129	CbGeAlD
Nilotinib—EPHB4—saliva-secreting gland—thyroid cancer	0.000297	0.0128	CbGeAlD
Nilotinib—CDC42BPB—head—thyroid cancer	0.000296	0.0127	CbGeAlD
Nilotinib—ABCB1—Doxorubicin—thyroid cancer	0.000294	0.001	CbGbCtD
Nilotinib—EPHA2—saliva-secreting gland—thyroid cancer	0.000292	0.0126	CbGeAlD
Nilotinib—CYP3A4—Sorafenib—thyroid cancer	0.000291	0.000989	CbGbCtD
Nilotinib—HCK—trachea—thyroid cancer	0.000289	0.0125	CbGeAlD
Nilotinib—CA7—trachea—thyroid cancer	0.000282	0.0122	CbGeAlD
Nilotinib—EPHA3—head—thyroid cancer	0.00028	0.0121	CbGeAlD
Nilotinib—CYP2D6—Doxorubicin—thyroid cancer	0.000277	0.000944	CbGbCtD
Nilotinib—MAP4K1—thyroid gland—thyroid cancer	0.000274	0.0118	CbGeAlD
Nilotinib—EPHB6—saliva-secreting gland—thyroid cancer	0.000272	0.0117	CbGeAlD
Nilotinib—MAPK8—head—thyroid cancer	0.000267	0.0115	CbGeAlD
Nilotinib—EPHA6—head—thyroid cancer	0.000267	0.0115	CbGeAlD
Nilotinib—KIT—neck—thyroid cancer	0.000264	0.0114	CbGeAlD
Nilotinib—EPHA4—trachea—thyroid cancer	0.000262	0.0113	CbGeAlD
Nilotinib—TIE1—thyroid gland—thyroid cancer	0.000261	0.0113	CbGeAlD
Nilotinib—PDGFRB—neck—thyroid cancer	0.000258	0.0111	CbGeAlD
Nilotinib—BRAF—thyroid gland—thyroid cancer	0.00025	0.0108	CbGeAlD
Nilotinib—LYN—head—thyroid cancer	0.000247	0.0106	CbGeAlD
Nilotinib—LCK—trachea—thyroid cancer	0.000241	0.0104	CbGeAlD
Nilotinib—BLK—lymph node—thyroid cancer	0.000237	0.0102	CbGeAlD
Nilotinib—MAP2K5—saliva-secreting gland—thyroid cancer	0.000233	0.01	CbGeAlD
Nilotinib—TIE1—head—thyroid cancer	0.000232	0.01	CbGeAlD
Nilotinib—EPHB4—trachea—thyroid cancer	0.000229	0.00989	CbGeAlD
Nilotinib—HCK—thyroid gland—thyroid cancer	0.000228	0.00985	CbGeAlD
Nilotinib—ABL2—thyroid gland—thyroid cancer	0.000227	0.00979	CbGeAlD
Nilotinib—EPHA2—trachea—thyroid cancer	0.000225	0.0097	CbGeAlD
Nilotinib—EPHB3—head—thyroid cancer	0.00022	0.00951	CbGeAlD
Nilotinib—EPHB6—trachea—thyroid cancer	0.00021	0.00905	CbGeAlD
Nilotinib—MAPK11—lymph node—thyroid cancer	0.000209	0.009	CbGeAlD
Nilotinib—EPHA4—thyroid gland—thyroid cancer	0.000208	0.00895	CbGeAlD
Nilotinib—CDC42BPB—lymph node—thyroid cancer	0.000207	0.00893	CbGeAlD
Nilotinib—KIT—saliva-secreting gland—thyroid cancer	0.000206	0.00889	CbGeAlD
Nilotinib—CA3—thyroid gland—thyroid cancer	0.000205	0.00884	CbGeAlD
Nilotinib—HCK—head—thyroid cancer	0.000203	0.00874	CbGeAlD
Nilotinib—PDGFRB—saliva-secreting gland—thyroid cancer	0.000201	0.00868	CbGeAlD
Nilotinib—PDGFRA—trachea—thyroid cancer	0.000199	0.00858	CbGeAlD
Nilotinib—EPHA3—lymph node—thyroid cancer	0.000196	0.00846	CbGeAlD
Nilotinib—CA6—head—thyroid cancer	0.000192	0.00828	CbGeAlD
Nilotinib—MAPK14—thyroid gland—thyroid cancer	0.000191	0.00825	CbGeAlD
Nilotinib—FGR—thyroid gland—thyroid cancer	0.000191	0.00822	CbGeAlD
Nilotinib—LCK—thyroid gland—thyroid cancer	0.000191	0.00822	CbGeAlD
Nilotinib—CA4—neck—thyroid cancer	0.000189	0.00815	CbGeAlD
Nilotinib—MAPK8—lymph node—thyroid cancer	0.000187	0.00807	CbGeAlD
Nilotinib—EPHA4—head—thyroid cancer	0.000184	0.00794	CbGeAlD
Nilotinib—CA12—trachea—thyroid cancer	0.000184	0.00791	CbGeAlD
Nilotinib—CA3—head—thyroid cancer	0.000182	0.00784	CbGeAlD
Nilotinib—EPHB4—thyroid gland—thyroid cancer	0.000181	0.00782	CbGeAlD
Nilotinib—ABL1—saliva-secreting gland—thyroid cancer	0.000179	0.00774	CbGeAlD
Nilotinib—MAP2K5—trachea—thyroid cancer	0.000179	0.00774	CbGeAlD
Nilotinib—EPHA2—thyroid gland—thyroid cancer	0.000178	0.00768	CbGeAlD
Nilotinib—CYP3A4—Doxorubicin—thyroid cancer	0.000176	0.0006	CbGbCtD
Nilotinib—CSF1R—trachea—thyroid cancer	0.000175	0.00755	CbGeAlD
Nilotinib—TEK—thyroid gland—thyroid cancer	0.000174	0.00749	CbGeAlD
Nilotinib—MAP4K1—lymph node—thyroid cancer	0.00017	0.00734	CbGeAlD
Nilotinib—MAPK14—head—thyroid cancer	0.00017	0.00732	CbGeAlD
Nilotinib—FGR—head—thyroid cancer	0.000169	0.00729	CbGeAlD
Nilotinib—EPHB6—thyroid gland—thyroid cancer	0.000166	0.00716	CbGeAlD
Nilotinib—TIE1—lymph node—thyroid cancer	0.000162	0.007	CbGeAlD
Nilotinib—KIT—trachea—thyroid cancer	0.000159	0.00686	CbGeAlD
Nilotinib—EPHA2—head—thyroid cancer	0.000158	0.00681	CbGeAlD
Nilotinib—PDGFRA—thyroid gland—thyroid cancer	0.000157	0.00678	CbGeAlD
Nilotinib—CA2—neck—thyroid cancer	0.000157	0.00675	CbGeAlD
Nilotinib—BRAF—lymph node—thyroid cancer	0.000156	0.00671	CbGeAlD
Nilotinib—PDGFRB—trachea—thyroid cancer	0.000155	0.0067	CbGeAlD
Nilotinib—EPHB3—lymph node—thyroid cancer	0.000154	0.00666	CbGeAlD
Nilotinib—TEK—head—thyroid cancer	0.000154	0.00664	CbGeAlD
Nilotinib—CA4—saliva-secreting gland—thyroid cancer	0.000147	0.00635	CbGeAlD
Nilotinib—EPHB6—head—thyroid cancer	0.000147	0.00635	CbGeAlD
Nilotinib—MAP2K5—thyroid gland—thyroid cancer	0.000142	0.00612	CbGeAlD
Nilotinib—HCK—lymph node—thyroid cancer	0.000142	0.00612	CbGeAlD
Nilotinib—ABL2—lymph node—thyroid cancer	0.000141	0.00608	CbGeAlD
Nilotinib—PDGFRA—head—thyroid cancer	0.00014	0.00602	CbGeAlD
Nilotinib—ABL1—Idarubicin—Epirubicin—thyroid cancer	0.000139	0.173	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Epirubicin—thyroid cancer	0.000139	0.173	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—thyroid cancer	0.000139	0.173	CbGdCrCtD
Nilotinib—CSF1R—thyroid gland—thyroid cancer	0.000138	0.00597	CbGeAlD
Nilotinib—ABL1—trachea—thyroid cancer	0.000138	0.00597	CbGeAlD
Nilotinib—EPHA4—lymph node—thyroid cancer	0.000129	0.00556	CbGeAlD
Nilotinib—CA12—head—thyroid cancer	0.000129	0.00555	CbGeAlD
Nilotinib—ABL1—Epirubicin—Doxorubicin—thyroid cancer	0.000128	0.16	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Doxorubicin—thyroid cancer	0.000128	0.16	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—thyroid cancer	0.000128	0.16	CbGdCrCtD
Nilotinib—CA3—lymph node—thyroid cancer	0.000127	0.00549	CbGeAlD
Nilotinib—MAP2K5—head—thyroid cancer	0.000126	0.00543	CbGeAlD
Nilotinib—KIT—thyroid gland—thyroid cancer	0.000126	0.00542	CbGeAlD
Nilotinib—CSF1R—head—thyroid cancer	0.000123	0.0053	CbGeAlD
Nilotinib—PDGFRB—thyroid gland—thyroid cancer	0.000123	0.0053	CbGeAlD
Nilotinib—CA2—saliva-secreting gland—thyroid cancer	0.000122	0.00527	CbGeAlD
Nilotinib—MAPK14—lymph node—thyroid cancer	0.000119	0.00513	CbGeAlD
Nilotinib—FGR—lymph node—thyroid cancer	0.000118	0.00511	CbGeAlD
Nilotinib—LCK—lymph node—thyroid cancer	0.000118	0.00511	CbGeAlD
Nilotinib—CA4—trachea—thyroid cancer	0.000114	0.0049	CbGeAlD
Nilotinib—ABCG2—saliva-secreting gland—thyroid cancer	0.000113	0.00488	CbGeAlD
Nilotinib—EPHB4—lymph node—thyroid cancer	0.000113	0.00486	CbGeAlD
Nilotinib—KIT—head—thyroid cancer	0.000112	0.00481	CbGeAlD
Nilotinib—EPHA2—lymph node—thyroid cancer	0.000111	0.00477	CbGeAlD
Nilotinib—ABL1—thyroid gland—thyroid cancer	0.000109	0.00472	CbGeAlD
Nilotinib—PDGFRB—head—thyroid cancer	0.000109	0.0047	CbGeAlD
Nilotinib—TEK—lymph node—thyroid cancer	0.000108	0.00465	CbGeAlD
Nilotinib—EPHB6—lymph node—thyroid cancer	0.000103	0.00445	CbGeAlD
Nilotinib—CA1—head—thyroid cancer	0.000102	0.0044	CbGeAlD
Nilotinib—PDGFRA—lymph node—thyroid cancer	9.77e-05	0.00421	CbGeAlD
Nilotinib—ABL1—head—thyroid cancer	9.71e-05	0.00419	CbGeAlD
Nilotinib—CA2—trachea—thyroid cancer	9.42e-05	0.00406	CbGeAlD
Nilotinib—CA4—thyroid gland—thyroid cancer	8.99e-05	0.00388	CbGeAlD
Nilotinib—MAP2K5—lymph node—thyroid cancer	8.81e-05	0.0038	CbGeAlD
Nilotinib—CSF1R—lymph node—thyroid cancer	8.6e-05	0.00371	CbGeAlD
Nilotinib—CA4—head—thyroid cancer	7.98e-05	0.00344	CbGeAlD
Nilotinib—KIT—lymph node—thyroid cancer	7.81e-05	0.00337	CbGeAlD
Nilotinib—PDGFRB—lymph node—thyroid cancer	7.63e-05	0.00329	CbGeAlD
Nilotinib—CA2—thyroid gland—thyroid cancer	7.45e-05	0.00321	CbGeAlD
Nilotinib—CA1—lymph node—thyroid cancer	7.14e-05	0.00308	CbGeAlD
Nilotinib—ABCG2—thyroid gland—thyroid cancer	6.9e-05	0.00298	CbGeAlD
Nilotinib—ABL1—lymph node—thyroid cancer	6.8e-05	0.00293	CbGeAlD
Nilotinib—CA2—head—thyroid cancer	6.61e-05	0.00285	CbGeAlD
Nilotinib—CYP2B6—head—thyroid cancer	5.65e-05	0.00244	CbGeAlD
Nilotinib—CA4—lymph node—thyroid cancer	5.58e-05	0.00241	CbGeAlD
Nilotinib—CA2—lymph node—thyroid cancer	4.63e-05	0.002	CbGeAlD
Nilotinib—ABCB1—trachea—thyroid cancer	4.3e-05	0.00186	CbGeAlD
Nilotinib—ABCG2—lymph node—thyroid cancer	4.29e-05	0.00185	CbGeAlD
Nilotinib—CYP2D6—head—thyroid cancer	4.2e-05	0.00181	CbGeAlD
Nilotinib—ABCB1—thyroid gland—thyroid cancer	3.4e-05	0.00147	CbGeAlD
Nilotinib—Abdominal pain upper—Epirubicin—thyroid cancer	3.15e-05	0.00065	CcSEcCtD
Nilotinib—Migraine—Doxorubicin—thyroid cancer	3.15e-05	0.000648	CcSEcCtD
Nilotinib—Hypokalaemia—Epirubicin—thyroid cancer	3.14e-05	0.000648	CcSEcCtD
Nilotinib—Diarrhoea—Sorafenib—thyroid cancer	3.14e-05	0.000648	CcSEcCtD
Nilotinib—Breast disorder—Epirubicin—thyroid cancer	3.12e-05	0.000643	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	3.11e-05	0.000641	CcSEcCtD
Nilotinib—Nasopharyngitis—Epirubicin—thyroid cancer	3.09e-05	0.000636	CcSEcCtD
Nilotinib—Face oedema—Doxorubicin—thyroid cancer	3.09e-05	0.000636	CcSEcCtD
Nilotinib—Gastritis—Epirubicin—thyroid cancer	3.06e-05	0.00063	CcSEcCtD
Nilotinib—Muscular weakness—Epirubicin—thyroid cancer	3.05e-05	0.000628	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	3.05e-05	0.000628	CcSEcCtD
Nilotinib—Dizziness—Sorafenib—thyroid cancer	3.04e-05	0.000626	CcSEcCtD
Nilotinib—ABCB1—head—thyroid cancer	3.02e-05	0.0013	CbGeAlD
Nilotinib—Abdominal distension—Epirubicin—thyroid cancer	3.01e-05	0.000619	CcSEcCtD
Nilotinib—Blood creatinine increased—Doxorubicin—thyroid cancer	2.99e-05	0.000617	CcSEcCtD
Nilotinib—Influenza—Epirubicin—thyroid cancer	2.99e-05	0.000615	CcSEcCtD
Nilotinib—Dehydration—Doxorubicin—thyroid cancer	2.97e-05	0.000612	CcSEcCtD
Nilotinib—Eosinophilia—Epirubicin—thyroid cancer	2.96e-05	0.000609	CcSEcCtD
Nilotinib—Dry skin—Doxorubicin—thyroid cancer	2.93e-05	0.000604	CcSEcCtD
Nilotinib—Pancreatitis—Epirubicin—thyroid cancer	2.93e-05	0.000603	CcSEcCtD
Nilotinib—Vomiting—Sorafenib—thyroid cancer	2.92e-05	0.000602	CcSEcCtD
Nilotinib—Abdominal pain upper—Doxorubicin—thyroid cancer	2.92e-05	0.000601	CcSEcCtD
Nilotinib—Hypokalaemia—Doxorubicin—thyroid cancer	2.91e-05	0.000599	CcSEcCtD
Nilotinib—Angina pectoris—Epirubicin—thyroid cancer	2.91e-05	0.000599	CcSEcCtD
Nilotinib—Rash—Sorafenib—thyroid cancer	2.9e-05	0.000597	CcSEcCtD
Nilotinib—Dermatitis—Sorafenib—thyroid cancer	2.89e-05	0.000596	CcSEcCtD
Nilotinib—Breast disorder—Doxorubicin—thyroid cancer	2.89e-05	0.000595	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	2.88e-05	0.000593	CcSEcCtD
Nilotinib—Headache—Sorafenib—thyroid cancer	2.88e-05	0.000593	CcSEcCtD
Nilotinib—Bronchitis—Epirubicin—thyroid cancer	2.87e-05	0.000592	CcSEcCtD
Nilotinib—Nasopharyngitis—Doxorubicin—thyroid cancer	2.86e-05	0.000589	CcSEcCtD
Nilotinib—Pancytopenia—Epirubicin—thyroid cancer	2.84e-05	0.000584	CcSEcCtD
Nilotinib—Gastritis—Doxorubicin—thyroid cancer	2.83e-05	0.000583	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	2.82e-05	0.000581	CcSEcCtD
Nilotinib—Muscular weakness—Doxorubicin—thyroid cancer	2.82e-05	0.000581	CcSEcCtD
Nilotinib—Neutropenia—Epirubicin—thyroid cancer	2.79e-05	0.000575	CcSEcCtD
Nilotinib—Dysuria—Epirubicin—thyroid cancer	2.79e-05	0.000575	CcSEcCtD
Nilotinib—Abdominal distension—Doxorubicin—thyroid cancer	2.78e-05	0.000573	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Epirubicin—thyroid cancer	2.77e-05	0.000572	CcSEcCtD
Nilotinib—Influenza—Doxorubicin—thyroid cancer	2.76e-05	0.000569	CcSEcCtD
Nilotinib—Pollakiuria—Epirubicin—thyroid cancer	2.76e-05	0.000568	CcSEcCtD
Nilotinib—Eosinophilia—Doxorubicin—thyroid cancer	2.73e-05	0.000564	CcSEcCtD
Nilotinib—Nausea—Sorafenib—thyroid cancer	2.73e-05	0.000562	CcSEcCtD
Nilotinib—Photosensitivity reaction—Epirubicin—thyroid cancer	2.73e-05	0.000561	CcSEcCtD
Nilotinib—Weight increased—Epirubicin—thyroid cancer	2.72e-05	0.00056	CcSEcCtD
Nilotinib—Pancreatitis—Doxorubicin—thyroid cancer	2.71e-05	0.000558	CcSEcCtD
Nilotinib—Weight decreased—Epirubicin—thyroid cancer	2.7e-05	0.000557	CcSEcCtD
Nilotinib—Hyperglycaemia—Epirubicin—thyroid cancer	2.69e-05	0.000555	CcSEcCtD
Nilotinib—Angina pectoris—Doxorubicin—thyroid cancer	2.69e-05	0.000554	CcSEcCtD
Nilotinib—Pneumonia—Epirubicin—thyroid cancer	2.68e-05	0.000552	CcSEcCtD
Nilotinib—Infestation NOS—Epirubicin—thyroid cancer	2.66e-05	0.000548	CcSEcCtD
Nilotinib—Infestation—Epirubicin—thyroid cancer	2.66e-05	0.000548	CcSEcCtD
Nilotinib—Bronchitis—Doxorubicin—thyroid cancer	2.66e-05	0.000547	CcSEcCtD
Nilotinib—Pancytopenia—Doxorubicin—thyroid cancer	2.62e-05	0.000541	CcSEcCtD
Nilotinib—Renal failure—Epirubicin—thyroid cancer	2.62e-05	0.000539	CcSEcCtD
Nilotinib—Neuropathy peripheral—Epirubicin—thyroid cancer	2.61e-05	0.000538	CcSEcCtD
Nilotinib—Stomatitis—Epirubicin—thyroid cancer	2.59e-05	0.000535	CcSEcCtD
Nilotinib—Jaundice—Epirubicin—thyroid cancer	2.59e-05	0.000535	CcSEcCtD
Nilotinib—Conjunctivitis—Epirubicin—thyroid cancer	2.59e-05	0.000533	CcSEcCtD
Nilotinib—Urinary tract infection—Epirubicin—thyroid cancer	2.59e-05	0.000533	CcSEcCtD
Nilotinib—Dysuria—Doxorubicin—thyroid cancer	2.58e-05	0.000532	CcSEcCtD
Nilotinib—Neutropenia—Doxorubicin—thyroid cancer	2.58e-05	0.000532	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	2.57e-05	0.000529	CcSEcCtD
Nilotinib—Pollakiuria—Doxorubicin—thyroid cancer	2.55e-05	0.000526	CcSEcCtD
Nilotinib—Haematuria—Epirubicin—thyroid cancer	2.54e-05	0.000523	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—thyroid cancer	2.52e-05	0.00052	CcSEcCtD
Nilotinib—Hepatobiliary disease—Epirubicin—thyroid cancer	2.52e-05	0.000519	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—thyroid cancer	2.51e-05	0.000518	CcSEcCtD
Nilotinib—Epistaxis—Epirubicin—thyroid cancer	2.51e-05	0.000517	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—thyroid cancer	2.5e-05	0.000515	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—thyroid cancer	2.49e-05	0.000513	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—thyroid cancer	2.48e-05	0.00051	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—thyroid cancer	2.46e-05	0.000507	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—thyroid cancer	2.46e-05	0.000507	CcSEcCtD
Nilotinib—Bradycardia—Epirubicin—thyroid cancer	2.43e-05	0.000501	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—thyroid cancer	2.42e-05	0.000499	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—thyroid cancer	2.41e-05	0.000497	CcSEcCtD
Nilotinib—Haemoglobin—Epirubicin—thyroid cancer	2.4e-05	0.000495	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—thyroid cancer	2.4e-05	0.000495	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—thyroid cancer	2.4e-05	0.000495	CcSEcCtD
Nilotinib—Rhinitis—Epirubicin—thyroid cancer	2.4e-05	0.000494	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—thyroid cancer	2.39e-05	0.000493	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—thyroid cancer	2.39e-05	0.000493	CcSEcCtD
Nilotinib—Haemorrhage—Epirubicin—thyroid cancer	2.39e-05	0.000492	CcSEcCtD
Nilotinib—Hepatitis—Epirubicin—thyroid cancer	2.39e-05	0.000492	CcSEcCtD
Nilotinib—Hypoaesthesia—Epirubicin—thyroid cancer	2.38e-05	0.00049	CcSEcCtD
Nilotinib—Pharyngitis—Epirubicin—thyroid cancer	2.37e-05	0.000489	CcSEcCtD
Nilotinib—Urinary tract disorder—Epirubicin—thyroid cancer	2.36e-05	0.000486	CcSEcCtD
Nilotinib—Oedema peripheral—Epirubicin—thyroid cancer	2.35e-05	0.000485	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—thyroid cancer	2.35e-05	0.000484	CcSEcCtD
Nilotinib—Connective tissue disorder—Epirubicin—thyroid cancer	2.35e-05	0.000484	CcSEcCtD
Nilotinib—Urethral disorder—Epirubicin—thyroid cancer	2.34e-05	0.000483	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	2.33e-05	0.00048	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—thyroid cancer	2.32e-05	0.000479	CcSEcCtD
Nilotinib—Visual impairment—Epirubicin—thyroid cancer	2.3e-05	0.000474	CcSEcCtD
Nilotinib—Erythema multiforme—Epirubicin—thyroid cancer	2.26e-05	0.000466	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—thyroid cancer	2.25e-05	0.000464	CcSEcCtD
Nilotinib—Eye disorder—Epirubicin—thyroid cancer	2.23e-05	0.00046	CcSEcCtD
Nilotinib—Tinnitus—Epirubicin—thyroid cancer	2.23e-05	0.000459	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—thyroid cancer	2.22e-05	0.000458	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—thyroid cancer	2.22e-05	0.000457	CcSEcCtD
Nilotinib—Flushing—Epirubicin—thyroid cancer	2.22e-05	0.000457	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—thyroid cancer	2.22e-05	0.000457	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—thyroid cancer	2.21e-05	0.000456	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—thyroid cancer	2.21e-05	0.000456	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—thyroid cancer	2.2e-05	0.000453	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—thyroid cancer	2.19e-05	0.000452	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—thyroid cancer	2.18e-05	0.00045	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—thyroid cancer	2.18e-05	0.000449	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—thyroid cancer	2.17e-05	0.000448	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—thyroid cancer	2.17e-05	0.000447	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—thyroid cancer	2.17e-05	0.000447	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—thyroid cancer	2.16e-05	0.000445	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—thyroid cancer	2.15e-05	0.000444	CcSEcCtD
Nilotinib—Chills—Epirubicin—thyroid cancer	2.14e-05	0.000442	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—thyroid cancer	2.13e-05	0.00044	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—thyroid cancer	2.13e-05	0.000439	CcSEcCtD
Nilotinib—ABCB1—lymph node—thyroid cancer	2.11e-05	0.000912	CbGeAlD
Nilotinib—Alopecia—Epirubicin—thyroid cancer	2.11e-05	0.000435	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—thyroid cancer	2.09e-05	0.000431	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—thyroid cancer	2.09e-05	0.000431	CcSEcCtD
Nilotinib—Erythema—Epirubicin—thyroid cancer	2.08e-05	0.000429	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—thyroid cancer	2.08e-05	0.000429	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—thyroid cancer	2.07e-05	0.000426	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—thyroid cancer	2.06e-05	0.000425	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—thyroid cancer	2.05e-05	0.000423	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—thyroid cancer	2.05e-05	0.000423	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—thyroid cancer	2.05e-05	0.000422	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—thyroid cancer	2.04e-05	0.00042	CcSEcCtD
Nilotinib—Back pain—Epirubicin—thyroid cancer	2.01e-05	0.000415	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—thyroid cancer	2.01e-05	0.000413	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—thyroid cancer	2e-05	0.000412	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—thyroid cancer	2e-05	0.000411	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—thyroid cancer	1.99e-05	0.000411	CcSEcCtD
Nilotinib—Chills—Doxorubicin—thyroid cancer	1.98e-05	0.000409	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—thyroid cancer	1.98e-05	0.000407	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—thyroid cancer	1.96e-05	0.000404	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—thyroid cancer	1.95e-05	0.000403	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—thyroid cancer	1.94e-05	0.000399	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—thyroid cancer	1.93e-05	0.000398	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—thyroid cancer	1.92e-05	0.000397	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—thyroid cancer	1.92e-05	0.000397	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—thyroid cancer	1.92e-05	0.000396	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—thyroid cancer	1.9e-05	0.000391	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—thyroid cancer	1.88e-05	0.000388	CcSEcCtD
Nilotinib—Malaise—Epirubicin—thyroid cancer	1.88e-05	0.000387	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—thyroid cancer	1.87e-05	0.000385	CcSEcCtD
Nilotinib—Syncope—Epirubicin—thyroid cancer	1.87e-05	0.000384	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—thyroid cancer	1.86e-05	0.000384	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—thyroid cancer	1.86e-05	0.000384	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—thyroid cancer	1.85e-05	0.000381	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—thyroid cancer	1.84e-05	0.000379	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—thyroid cancer	1.83e-05	0.000377	CcSEcCtD
Nilotinib—Cough—Epirubicin—thyroid cancer	1.82e-05	0.000374	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—thyroid cancer	1.81e-05	0.000374	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—thyroid cancer	1.8e-05	0.00037	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—thyroid cancer	1.79e-05	0.000368	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—thyroid cancer	1.78e-05	0.000367	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—thyroid cancer	1.77e-05	0.000365	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—thyroid cancer	1.77e-05	0.000365	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—thyroid cancer	1.77e-05	0.000365	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—thyroid cancer	1.76e-05	0.000364	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	1.76e-05	0.000362	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—thyroid cancer	1.75e-05	0.000361	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—thyroid cancer	1.74e-05	0.000358	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—thyroid cancer	1.73e-05	0.000357	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—thyroid cancer	1.73e-05	0.000356	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—thyroid cancer	1.73e-05	0.000356	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—thyroid cancer	1.72e-05	0.000355	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—thyroid cancer	1.71e-05	0.000353	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—thyroid cancer	1.7e-05	0.00035	CcSEcCtD
Nilotinib—Oedema—Epirubicin—thyroid cancer	1.7e-05	0.00035	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—thyroid cancer	1.69e-05	0.000349	CcSEcCtD
Nilotinib—Infection—Epirubicin—thyroid cancer	1.69e-05	0.000348	CcSEcCtD
Nilotinib—Cough—Doxorubicin—thyroid cancer	1.68e-05	0.000346	CcSEcCtD
Nilotinib—Shock—Epirubicin—thyroid cancer	1.67e-05	0.000344	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—thyroid cancer	1.66e-05	0.000343	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—thyroid cancer	1.66e-05	0.000342	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—thyroid cancer	1.66e-05	0.000342	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—thyroid cancer	1.66e-05	0.000341	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—thyroid cancer	1.65e-05	0.00034	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—thyroid cancer	1.64e-05	0.000338	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—thyroid cancer	1.64e-05	0.000338	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—thyroid cancer	1.64e-05	0.000338	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—thyroid cancer	1.64e-05	0.000338	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—thyroid cancer	1.63e-05	0.000336	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	1.63e-05	0.000335	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—thyroid cancer	1.62e-05	0.000334	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—thyroid cancer	1.62e-05	0.000333	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—thyroid cancer	1.6e-05	0.00033	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—thyroid cancer	1.59e-05	0.000327	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—thyroid cancer	1.58e-05	0.000326	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—thyroid cancer	1.57e-05	0.000324	CcSEcCtD
Nilotinib—Infection—Doxorubicin—thyroid cancer	1.56e-05	0.000322	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	1.55e-05	0.000319	CcSEcCtD
Nilotinib—Shock—Doxorubicin—thyroid cancer	1.55e-05	0.000318	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—thyroid cancer	1.54e-05	0.000317	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—thyroid cancer	1.54e-05	0.000317	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—thyroid cancer	1.54e-05	0.000316	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—thyroid cancer	1.53e-05	0.000316	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—thyroid cancer	1.53e-05	0.000314	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—thyroid cancer	1.52e-05	0.000314	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—thyroid cancer	1.52e-05	0.000313	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—thyroid cancer	1.51e-05	0.000312	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—thyroid cancer	1.5e-05	0.000309	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—thyroid cancer	1.49e-05	0.000308	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—thyroid cancer	1.48e-05	0.000304	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—thyroid cancer	1.47e-05	0.000302	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	1.47e-05	0.000302	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—thyroid cancer	1.46e-05	0.000302	CcSEcCtD
Nilotinib—Pain—Epirubicin—thyroid cancer	1.45e-05	0.000299	CcSEcCtD
Nilotinib—Constipation—Epirubicin—thyroid cancer	1.45e-05	0.000299	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	1.43e-05	0.000295	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—thyroid cancer	1.42e-05	0.000293	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—thyroid cancer	1.41e-05	0.000291	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—thyroid cancer	1.4e-05	0.000289	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—thyroid cancer	1.4e-05	0.000288	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—thyroid cancer	1.39e-05	0.000286	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—thyroid cancer	1.38e-05	0.000285	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—thyroid cancer	1.37e-05	0.000281	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	1.36e-05	0.000279	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—thyroid cancer	1.35e-05	0.000279	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—thyroid cancer	1.35e-05	0.000278	CcSEcCtD
Nilotinib—Pain—Doxorubicin—thyroid cancer	1.34e-05	0.000277	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—thyroid cancer	1.34e-05	0.000277	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—thyroid cancer	1.34e-05	0.000277	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—thyroid cancer	1.34e-05	0.000277	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—thyroid cancer	1.29e-05	0.000267	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	1.28e-05	0.000265	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—thyroid cancer	1.25e-05	0.000258	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—thyroid cancer	1.25e-05	0.000257	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—thyroid cancer	1.24e-05	0.000256	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—thyroid cancer	1.24e-05	0.000256	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—thyroid cancer	1.22e-05	0.000251	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—thyroid cancer	1.2e-05	0.000247	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—thyroid cancer	1.16e-05	0.000239	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—thyroid cancer	1.16e-05	0.000238	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—thyroid cancer	1.13e-05	0.000232	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—thyroid cancer	1.12e-05	0.000231	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—thyroid cancer	1.11e-05	0.000229	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—thyroid cancer	1.08e-05	0.000222	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—thyroid cancer	1.07e-05	0.000221	CcSEcCtD
Nilotinib—Rash—Epirubicin—thyroid cancer	1.07e-05	0.000221	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—thyroid cancer	1.07e-05	0.00022	CcSEcCtD
Nilotinib—Headache—Epirubicin—thyroid cancer	1.06e-05	0.000219	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—thyroid cancer	1.04e-05	0.000214	CcSEcCtD
Nilotinib—Nausea—Epirubicin—thyroid cancer	1.01e-05	0.000208	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—thyroid cancer	9.99e-06	0.000206	CcSEcCtD
Nilotinib—Rash—Doxorubicin—thyroid cancer	9.9e-06	0.000204	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—thyroid cancer	9.9e-06	0.000204	CcSEcCtD
Nilotinib—Headache—Doxorubicin—thyroid cancer	9.84e-06	0.000203	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—thyroid cancer	9.33e-06	0.000192	CcSEcCtD
Nilotinib—CA7—Metabolism—AKT1—thyroid cancer	1.61e-06	3.97e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TERT—thyroid cancer	1.59e-06	3.92e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TPR—thyroid cancer	1.58e-06	3.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—HRAS—thyroid cancer	1.57e-06	3.87e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TPR—thyroid cancer	1.56e-06	3.85e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—AKT1—thyroid cancer	1.56e-06	3.85e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PTEN—thyroid cancer	1.56e-06	3.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HIF1A—thyroid cancer	1.55e-06	3.83e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.55e-06	3.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—AKT1—thyroid cancer	1.54e-06	3.79e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—HRAS—thyroid cancer	1.54e-06	3.79e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—AKT1—thyroid cancer	1.54e-06	3.79e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.54e-06	3.79e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCND1—thyroid cancer	1.53e-06	3.78e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—HRAS—thyroid cancer	1.53e-06	3.77e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—AKT1—thyroid cancer	1.53e-06	3.77e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—HRAS—thyroid cancer	1.52e-06	3.75e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HIF1A—thyroid cancer	1.52e-06	3.75e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTEN—thyroid cancer	1.52e-06	3.74e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—BRAF—thyroid cancer	1.51e-06	3.72e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HRAS—thyroid cancer	1.51e-06	3.72e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—AKT1—thyroid cancer	1.51e-06	3.72e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TERT—thyroid cancer	1.51e-06	3.72e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—AKT1—thyroid cancer	1.5e-06	3.7e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HRAS—thyroid cancer	1.49e-06	3.68e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—HRAS—thyroid cancer	1.49e-06	3.68e-05	CbGpPWpGaD
Nilotinib—CA12—Metabolism—AKT1—thyroid cancer	1.49e-06	3.68e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—HRAS—thyroid cancer	1.49e-06	3.67e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—NRAS—thyroid cancer	1.49e-06	3.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—thyroid cancer	1.49e-06	3.66e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—KRAS—thyroid cancer	1.48e-06	3.66e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PTEN—thyroid cancer	1.48e-06	3.65e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—AKT1—thyroid cancer	1.48e-06	3.64e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HRAS—thyroid cancer	1.48e-06	3.64e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—BRAF—thyroid cancer	1.48e-06	3.63e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—NRAS—thyroid cancer	1.47e-06	3.61e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—thyroid cancer	1.47e-06	3.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HRAS—thyroid cancer	1.46e-06	3.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—AKT1—thyroid cancer	1.46e-06	3.59e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCND1—thyroid cancer	1.46e-06	3.59e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—AKT1—thyroid cancer	1.46e-06	3.59e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRG1—thyroid cancer	1.45e-06	3.58e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PPARG—thyroid cancer	1.45e-06	3.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HIF1A—thyroid cancer	1.44e-06	3.55e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.44e-06	3.54e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTEN—thyroid cancer	1.44e-06	3.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—AKT1—thyroid cancer	1.43e-06	3.52e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—BRAF—thyroid cancer	1.43e-06	3.52e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—RXRA—thyroid cancer	1.43e-06	3.51e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KRAS—thyroid cancer	1.43e-06	3.51e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.41e-06	3.48e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PTEN—thyroid cancer	1.41e-06	3.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PTEN—thyroid cancer	1.4e-06	3.46e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—HRAS—thyroid cancer	1.4e-06	3.45e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—KRAS—thyroid cancer	1.4e-06	3.45e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.39e-06	3.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NRAS—thyroid cancer	1.39e-06	3.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—AKT1—thyroid cancer	1.39e-06	3.42e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—PTEN—thyroid cancer	1.37e-06	3.38e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PTEN—thyroid cancer	1.37e-06	3.37e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—AKT1—thyroid cancer	1.36e-06	3.35e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NRAS—thyroid cancer	1.36e-06	3.34e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—AKT1—thyroid cancer	1.35e-06	3.33e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.35e-06	3.32e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—AKT1—thyroid cancer	1.34e-06	3.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—AKT1—thyroid cancer	1.33e-06	3.28e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NRAS—thyroid cancer	1.32e-06	3.25e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—AKT1—thyroid cancer	1.32e-06	3.25e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—AKT1—thyroid cancer	1.32e-06	3.25e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—AKT1—thyroid cancer	1.32e-06	3.24e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—AKT1—thyroid cancer	1.31e-06	3.21e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TERT—thyroid cancer	1.3e-06	3.21e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PTEN—thyroid cancer	1.3e-06	3.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTEN—thyroid cancer	1.3e-06	3.19e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—AKT1—thyroid cancer	1.29e-06	3.17e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—BRAF—thyroid cancer	1.29e-06	3.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NRAS—thyroid cancer	1.28e-06	3.16e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—KRAS—thyroid cancer	1.28e-06	3.16e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—KRAS—thyroid cancer	1.26e-06	3.11e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HRAS—thyroid cancer	1.26e-06	3.11e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—BRAF—thyroid cancer	1.26e-06	3.1e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	1.26e-06	3.09e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.25e-06	3.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NRAS—thyroid cancer	1.25e-06	3.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HIF1A—thyroid cancer	1.25e-06	3.07e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—AKT1—thyroid cancer	1.24e-06	3.05e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PPARG—thyroid cancer	1.23e-06	3.03e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NRAS—thyroid cancer	1.23e-06	3.02e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCND1—thyroid cancer	1.22e-06	3.01e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NRAS—thyroid cancer	1.22e-06	3e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—thyroid cancer	1.21e-06	2.98e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCND1—thyroid cancer	1.21e-06	2.98e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—RXRA—thyroid cancer	1.21e-06	2.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KRAS—thyroid cancer	1.2e-06	2.94e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—BRAF—thyroid cancer	1.2e-06	2.94e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—thyroid cancer	1.19e-06	2.94e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—thyroid cancer	1.19e-06	2.93e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—thyroid cancer	1.19e-06	2.93e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.18e-06	2.91e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTEN—thyroid cancer	1.18e-06	2.91e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.18e-06	2.89e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.17e-06	2.88e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTEN—thyroid cancer	1.17e-06	2.88e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—KRAS—thyroid cancer	1.17e-06	2.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NRAS—thyroid cancer	1.16e-06	2.86e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NRAS—thyroid cancer	1.16e-06	2.85e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—thyroid cancer	1.14e-06	2.81e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—thyroid cancer	1.14e-06	2.81e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KRAS—thyroid cancer	1.14e-06	2.8e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PTEN—thyroid cancer	1.13e-06	2.77e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—thyroid cancer	1.11e-06	2.74e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KRAS—thyroid cancer	1.1e-06	2.72e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—thyroid cancer	1.1e-06	2.71e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.1e-06	2.7e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—thyroid cancer	1.09e-06	2.69e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—thyroid cancer	1.09e-06	2.68e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	1.08e-06	2.66e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KRAS—thyroid cancer	1.08e-06	2.65e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—thyroid cancer	1.07e-06	2.64e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—thyroid cancer	1.07e-06	2.63e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTEN—thyroid cancer	1.06e-06	2.62e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KRAS—thyroid cancer	1.05e-06	2.6e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—RXRA—thyroid cancer	1.05e-06	2.59e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NRAS—thyroid cancer	1.05e-06	2.59e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—thyroid cancer	1.05e-06	2.59e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KRAS—thyroid cancer	1.05e-06	2.59e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—thyroid cancer	1.05e-06	2.57e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—thyroid cancer	1.04e-06	2.57e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NRAS—thyroid cancer	1.04e-06	2.57e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTEN—thyroid cancer	1.04e-06	2.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BRAF—thyroid cancer	1.03e-06	2.54e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TPR—thyroid cancer	1.03e-06	2.54e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—thyroid cancer	1.02e-06	2.5e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.01e-06	2.5e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—thyroid cancer	1.01e-06	2.49e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTEN—thyroid cancer	1.01e-06	2.48e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NRAS—thyroid cancer	1e-06	2.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—thyroid cancer	1e-06	2.46e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—thyroid cancer	9.95e-07	2.45e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTEN—thyroid cancer	9.94e-07	2.45e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—RXRA—thyroid cancer	9.92e-07	2.44e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—thyroid cancer	9.91e-07	2.44e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—RXRA—thyroid cancer	9.83e-07	2.42e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—thyroid cancer	9.67e-07	2.38e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—thyroid cancer	9.66e-07	2.38e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—thyroid cancer	9.62e-07	2.37e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—thyroid cancer	9.62e-07	2.37e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	9.61e-07	2.37e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.56e-07	2.36e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—thyroid cancer	9.49e-07	2.34e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—thyroid cancer	9.48e-07	2.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—thyroid cancer	9.4e-07	2.31e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—thyroid cancer	9.38e-07	2.31e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—thyroid cancer	9.27e-07	2.28e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—thyroid cancer	9.2e-07	2.27e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	9.19e-07	2.26e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—thyroid cancer	9.16e-07	2.26e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—thyroid cancer	9.07e-07	2.23e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—thyroid cancer	9.06e-07	2.23e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—thyroid cancer	9.01e-07	2.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—thyroid cancer	8.98e-07	2.21e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—thyroid cancer	8.97e-07	2.21e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—thyroid cancer	8.97e-07	2.21e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—thyroid cancer	8.96e-07	2.21e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—thyroid cancer	8.92e-07	2.2e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—thyroid cancer	8.88e-07	2.19e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—thyroid cancer	8.75e-07	2.16e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—thyroid cancer	8.72e-07	2.15e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—thyroid cancer	8.65e-07	2.13e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—thyroid cancer	8.53e-07	2.1e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—thyroid cancer	8.5e-07	2.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—thyroid cancer	8.45e-07	2.08e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—thyroid cancer	8.43e-07	2.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—thyroid cancer	8.42e-07	2.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—thyroid cancer	8.29e-07	2.04e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—thyroid cancer	8.17e-07	2.01e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	8.11e-07	2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—thyroid cancer	8.09e-07	1.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—thyroid cancer	8.09e-07	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—thyroid cancer	8.05e-07	1.98e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—thyroid cancer	7.98e-07	1.97e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—thyroid cancer	7.97e-07	1.96e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—thyroid cancer	7.92e-07	1.95e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—thyroid cancer	7.92e-07	1.95e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—thyroid cancer	7.88e-07	1.94e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—thyroid cancer	7.73e-07	1.9e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	7.72e-07	1.9e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—thyroid cancer	7.7e-07	1.9e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—thyroid cancer	7.63e-07	1.88e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—thyroid cancer	7.63e-07	1.88e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—thyroid cancer	7.54e-07	1.86e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—thyroid cancer	7.51e-07	1.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—thyroid cancer	7.5e-07	1.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—thyroid cancer	7.46e-07	1.84e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—thyroid cancer	7.46e-07	1.84e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—thyroid cancer	7.35e-07	1.81e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—thyroid cancer	7.28e-07	1.79e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—thyroid cancer	7.26e-07	1.79e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—thyroid cancer	7.09e-07	1.75e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—thyroid cancer	6.96e-07	1.72e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—thyroid cancer	6.94e-07	1.71e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—thyroid cancer	6.87e-07	1.69e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—thyroid cancer	6.82e-07	1.68e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—thyroid cancer	6.8e-07	1.67e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—thyroid cancer	6.78e-07	1.67e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—thyroid cancer	6.73e-07	1.66e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—thyroid cancer	6.65e-07	1.64e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—thyroid cancer	6.57e-07	1.62e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—thyroid cancer	6.49e-07	1.6e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—thyroid cancer	6.49e-07	1.6e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—RXRA—thyroid cancer	6.49e-07	1.6e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—thyroid cancer	6.46e-07	1.59e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—thyroid cancer	6.26e-07	1.54e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—thyroid cancer	6.21e-07	1.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—thyroid cancer	6.19e-07	1.52e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—thyroid cancer	6.18e-07	1.52e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—thyroid cancer	6.13e-07	1.51e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—thyroid cancer	6.06e-07	1.49e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—thyroid cancer	6e-07	1.48e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—thyroid cancer	5.99e-07	1.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—thyroid cancer	5.92e-07	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—thyroid cancer	5.8e-07	1.43e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—thyroid cancer	5.8e-07	1.43e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—thyroid cancer	5.75e-07	1.42e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—thyroid cancer	5.73e-07	1.41e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—thyroid cancer	5.59e-07	1.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—thyroid cancer	5.49e-07	1.35e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—thyroid cancer	5.23e-07	1.29e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—thyroid cancer	5.23e-07	1.29e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—thyroid cancer	5.23e-07	1.29e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—thyroid cancer	5.12e-07	1.26e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—thyroid cancer	4.97e-07	1.22e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—thyroid cancer	4.93e-07	1.21e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—thyroid cancer	4.88e-07	1.2e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—thyroid cancer	4.86e-07	1.2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—thyroid cancer	4.85e-07	1.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—thyroid cancer	4.75e-07	1.17e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—thyroid cancer	4.56e-07	1.12e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—thyroid cancer	4.3e-07	1.06e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—thyroid cancer	4.26e-07	1.05e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—thyroid cancer	4.19e-07	1.03e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—thyroid cancer	4.09e-07	1.01e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—thyroid cancer	3.56e-07	8.77e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.22e-07	7.93e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—thyroid cancer	3.02e-07	7.43e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—thyroid cancer	2.81e-07	6.92e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—thyroid cancer	2.63e-07	6.47e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—thyroid cancer	2.48e-07	6.1e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—thyroid cancer	2.45e-07	6.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—thyroid cancer	1.62e-07	3.99e-06	CbGpPWpGaD
